Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2023-12-12 00:00:00 ET · period of report 2023-12-08 · accession 0001883850-23-000089 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-12-12 | 2023-12-08+ | REGN | MURPHY ANDREW J | EVP Research | F - Tax | $844.05 | -6,657 | 58.5K | -10% | -$5.62M |
| D | 2023-12-12 | 2023-12-08 | REGN | MURPHY ANDREW J | EVP Research | A - Grant | $0.00 | +3,199 | 61.7K | +5% | $0 |
| D | 2023-12-12 | 2023-12-08 | REGN | MURPHY ANDREW J | EVP Research | A - Grant | $0.00 | +11.5K | 11.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-11 | F | D | 669 | $844.09 | 55,963 | D | — | — | |
| 2 | Common | Common Stock | 2023-12-11 | F | D | 5,105 | $844.09 | 56,632 | D | — | — | |
| 3 | Common | Common Stock | 2023-12-08 | A | A | 3,199 | $0.00 | 61,737 | D | — | — | |
| 4 | Common | Common Stock | 2023-12-08 | F | D | 883 | $843.79 | 58,538 | D | — | — | |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2023-12-08 | A | A | 11,473 | $0.00 | 11,473 | D | $843.79 · — to 2033-12-08 | 11,473 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |